ArticleJournal of biosciences2022
TEAD4 overexpression suppresses thyroid cancer progression and metastasis
Article in Journal of biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Two Cohorts, One Network: Consensus Master Regulators Orchestrating Papillary Thyroid Carcinoma.International journal of molecular sciences · 2025Article
- A Four-Gene Prognostic Signature Based on the TEAD4 Differential Expression Predicts Overall Survival and Immune Microenvironment Estimation in Lung Adenocarcinoma.Frontiers in pharmacology · 2022Article
- TEAD4 as an Oncogene and a Mitochondrial Modulator.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TEAD4 has been reported to act as an oncogenic gene in various types of cancer. This study intends to investigate the role and regulatory mechanism of TEAD4 in thyroid cancer (TC). GEPIA was used to predict the expression pattern of TEAD4 in TC. Expressions of TEAD4 and wnt3a in TC tissues and cells were analyzed by qRT-PCR and Western blot. TC cells were transfected with TEAD4 overexpression plasmids and treated with or without IWR-1-endo (a Wnt signaling inhibitor), and then TC cell viability, migration and invasion were assessed by MTT and Transwell assay. Expressions of E-cadherin, N-cadherin and Vimentin in cells were analyzed by Western blot. TEAD4 was low-expressed in TC tissues and cells. TEAD4 overexpression inhibited the viability, inhibited migration and invasion of TC cells, and downregulated N-cadherin and Vimentin expression, while promoted E-cadherin and wnt3a expression. The wnt3a expression was positively correlated with TEAD4 expression in TC. IWR-1-endo treatment reversed the effect of TEAD4 in TC cells. TEAD4 overexpression suppresses TC progression and metastasis in vitro through modulating Wnt signaling.
Indexed as
Identifiers
34951409W4200486359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.